The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
April 29th 2025
A novel orally bioavailable RIPTAC therapeutic targeting the p53-Y220C mutation demonstrates selective cancer cell killing by inducing proximity between mutant p53 and an essential protein, offering a promising new strategy for treating historically untreatable tumors.
Avella Specialty Pharmacy: Overcoming Oncology Adherence Barriers
June 18th 2013Specialty Pharmacy Times sat down to talk with Dr. Eric Sredzinski about the controversial topic of pricing for oncology medications, as well as common patient reimbursement hurdles and Avella's technologically savvy efforts to break down patient adherence barriers.
Read More
Welcome to our third annual special Oncology edition of Specialty Pharmacy Times! While new targeted oral medications are convenient and effective, they are also expensive and toxic, so the need for creating the greatest effectiveness from therapy is warranted. That's where specialty pharmacy comes in.
Read More